Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 3Brain Neoplasms 2Pituitary Neoplasms 1Non-Melanoma Skin Cancer (NMSC) 1Neuroectodermal Tumors 1Neoplasms, Neuroepithelial 1Neoplasms 1Neoplasm, Residual 1Keratosis, Actinic 1Central Nervous System Neoplasms 1

Interventions

Surveys and Questionnaires 86Blood Specimen Collection 58Interviews as Topic 28Observation 15Data Collection 15Radiotherapy 12Watchful Waiting 11Magnetic Resonance Spectroscopy 11Hematologic Tests 11Exercise 11Drug Therapy 11Quality of Life 9Biopsy 8Specimen Handling 7Therapeutics 6Restraint, Physical 6Magnetic Resonance Imaging 6Focus Groups 6pembrolizumab 5Standard of Care 5Rivaroxaban 5Phlebotomy 5Nivolumab 5Lapatinib 5Immune Checkpoint Inhibitors 5atezolizumab 4apixaban 4Trastuzumab 4Patient Reported Outcome Measures 4Palliative Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Neoplasms × Aminolevulinic Acid × Clear all
NCT05850377 2023-05-09

5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas

Sociedad de Lucha Contra el Cáncer del Ecuador

Not yet recruiting
90 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms, Central Nervous System Neoplasms, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡